Tango Therapeutics

Tango Therapeutics

  • Founded: 2016
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: Oncology
  • Drug types: ONC
  • Lead product: TNG908
  • Product link: https://www.tangotx.com/pipeline/
  • Funding: $80M stock Aug 2023; $50M Aug 2020; $60M B Apr 2020; $55M Mar 2017



job board

Short description:

Cancer Therapeutics, Immuno-Oncology

Drug notes:

TNG462 Clin1/Clin2 oncology; TNG260 Clin1/Clin2 oncology; TNG348 Clin0 cancers

Long description:

Tango Therapeutics is using the principle of synthetic lethality to develop medicines for cancer patients. Synthetic lethality describes a situation where loss of two targets results in cell death, while loss of either one alone does not. Since some tumors already possess target loss, Tango is using their CRISPR-based functional genomics target discovery platform and analytic pipeline to identify novel synthetic lethal targets that can selectively kill tumor cells. Tango is applying this approach in two core areas: [1] tumor suppressor gene loss and [2] immune evasion. Once targets are identified, Tango screens for drugs that have therapeutic potential. Tango’s lead candidate, TNG908, is being evaluated in clinical trials for MTAP-deleted tumors.


Tango Therapeutics
Associate Scientist I/II, Immunology
Boston, MA|24 days ago
Tango Therapeutics
VP, Clinical Data Management & Standards
Boston, MA|31 days ago
Tango Therapeutics
Director/Senior Director, Clinical Pharmacology
Boston, MA|37 days ago
Tango Therapeutics
Staff Accountant
Boston, MA|100+ days ago
Tango Therapeutics
Director, Clinical Operations
Boston, MA|100+ days ago
Tango Therapeutics
Clinical Trial Manager
Boston, MA|100+ days ago
Tango Therapeutics
Director, GXP Quality
Boston, MA|100+ days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com